Unjha Formulations Ltd
Unjha Formulations Ltd (UNJHAFOR) last reported results for the quarter ended Jun 2026, with sales of ₹3.31 crore and net profit of ₹0.16 crore. The stock last traded at ₹32, a market capitalisation of ₹14.3 crore, on a P/E of 29.9. Over the past 52 weeks the stock has ranged between ₹17.5 and ₹36.4. Figures are as of 6 Oct 2026 and are not real time.
Unjha Formulations Ltd share price and key metrics
- Current price
- ₹32
- Market cap
- ₹14.3 cr
- Stock P/E
- 29.9
- Book value
- ₹8.57
- ROE
- 20.1%
- ROCE
- 27.8%
- Dividend yield
- 0.00%
- 52w high / low
- 36.4/17.5
Metrics as of 6 Oct 2026. Not real time.
Track Unjha Formulations Ltd
Cruxal reads every Unjha Formulations Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Unjha Formulations Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- 13%
- 10 Years
- 10%
- 5 Years
- 48%
- 3 Years
- 36%
- TTM
- 433%
- 10 Years
- 10%
- 5 Years
- 23%
- 3 Years
- 25%
- 1 Year
- 26%
- 10 Years
- 16%
- 5 Years
- 14%
- 3 Years
- 15%
- Last Year
- 20%
Unjha Formulations Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹3.31 cr, down 8.8% from ₹3.63 cr a year earlier. Net profit was ₹0.16 cr, down 59.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.78 | 3.76 | 2.44 | 3.63 | 4.29 | 4.44 | 3.33 | 3.31 |
| Expenses | 3.89 | 3.52 | 2.7 | 3.21 | 3.5 | 4.16 | 3.78 | 3.12 |
| Operating profit | -0.11 | 0.24 | -0.26 | 0.42 | 0.79 | 0.28 | -0.45 | 0.19 |
| OPM % | -2.91% | 6.38% | -10.66% | 11.57% | 18.41% | 6.31% | -13.51% | 5.74% |
| Other income | 0.02 | 0.01 | 0 | 0 | 0.06 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.11 | 0.23 | -0.29 | 0.39 | 0.82 | 0.24 | -0.49 | 0.15 |
| Tax % | 0.00% | 0.00% | 41.38% | 0.00% | 0.00% | 0.00% | 51.02% | 0.00% |
| Net profit | -0.11 | 0.22 | -0.41 | 0.39 | 0.82 | 0.24 | -0.74 | 0.16 |
| EPS (₹) | -0.25 | 0.49 | -0.92 | 0.87 | 1.83 | 0.54 | -1.65 | 0.36 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Unjha Formulations Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.23 | 11.3 | 11.28 | 10.59 | 9.96 | 14.16 | 13.15 | 18.5 | 13.86 | 15.59 | 15.37 |
| Operating profit | 0.37 | 0.34 | 0.3 | 0.25 | 0.13 | 0.32 | 0.44 | 0.57 | 0.52 | 0.95 | 0.81 |
| OPM % | 3.03% | 3.01% | 2.66% | 2.36% | 1.31% | 2.26% | 3.35% | 3.08% | 3.75% | 6.09% | 5.27% |
| Net profit | 0.3 | 0.26 | 0.3 | 0.31 | 0.1 | 0.25 | 0.28 | 0.28 | 0.41 | 0.7 | 0.48 |
| EPS (₹) | 0.67 | 0.58 | 0.67 | 0.69 | 0.22 | 0.56 | 0.62 | 0.62 | 0.92 | 1.56 | 1.08 |
TTM is the trailing twelve months to the most recent quarter.
Unjha Formulations Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 |
| Reserves | -3.54 | -3.27 | -2.97 | -2.67 | -2.56 | -2.31 | -2.03 | -1.75 | -1.34 | -0.64 |
| Borrowings | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other liabilities | 2.79 | 2.75 | 2.15 | 1.90 | 1.61 | 1.28 | 0.96 | 2.20 | 1.42 | 1.67 |
| Total liabilities | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 | 4.93 | 4.56 | 5.51 |
| Fixed assets | 1.22 | 1.16 | 1.12 | 1.14 | 1.12 | 1.07 | 1.10 | 1.12 | 1.20 | 1.30 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 2.56 | 2.80 | 2.54 | 2.57 | 2.41 | 2.38 | 2.31 | 3.81 | 3.36 | 4.21 |
| Total assets | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 | 4.93 | 4.56 | 5.51 |
As reported by the company. Total assets equal total liabilities by construction.
Unjha Formulations Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.39 | 0.14 | -0.12 | 0.39 | -0.70 | 0.28 | -0.26 | 1.03 | -0.04 | 1.24 |
| Cash from investing | -0.28 | 0.06 | 0.04 | -0.10 | -0.06 | -0.02 | -0.10 | -0.11 | -0.18 | -0.23 |
| Cash from financing | 0.05 | -0.05 | 0.23 | 0.00 | 0.00 | 0.00 | -0.06 | -0.05 | -0.01 | -0.01 |
| Net cash flow | 0.15 | 0.15 | 0.16 | 0.29 | -0.77 | 0.25 | -0.42 | 0.86 | -0.23 | 1.00 |
| Free cash flow | 0.11 | 0.20 | -0.08 | 0.29 | -0.76 | 0.26 | -0.36 | 0.92 | -0.22 | 1.01 |
| CFO / operating profit | 105% | 41% | -37% | 204% | -408% | 88% | -48% | 189% | 19% | 156% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Unjha Formulations Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 47.56% | 25.45% | 22.79% | 25.90% | 14.48% | 21.03% | 16.88% | 19.31% | 18.06% | 27.79% |
| Debtor days | 19.40 | 25.19 | 43.36 | 39.64 | 35.91 | 18.04 | 29.14 | 31.76 | 39.77 | 31.61 |
| Inventory days | 40.83 | 39.40 | 22.92 | 21.37 | 55.60 | 34.08 | 38.92 | 29.56 | 32.92 | 19.10 |
| Days payable | 98.20 | 106.22 | 87.50 | 82.79 | 77.35 | 39.81 | 32.10 | 47.85 | 37.39 | 39.71 |
| Cash conversion cycle | -37.97 | -41.63 | -21.22 | -21.79 | 14.16 | 12.31 | 35.97 | 13.47 | 35.29 | 10.99 |
| Working capital days | -24.17 | -21.96 | -8.41 | -9.31 | 22.72 | 17.27 | 37.19 | 14.60 | 34.24 | 21.31 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Unjha Formulations Ltd shareholding pattern
Promoters held 36.92% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% |
| Public | 63.07% | 63.07% | 63.07% | 63.08% | 63.08% | 63.08% | 63.08% | 63.07% |
| No. of shareholders | 3,969 | 4,208 | 4,273 | 4,213 | 4,284 | 4,251 | 4,235 | 4,223 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Unjha Formulations Ltd corporate filings
- Compliance Certificate under Regulation 74(5) of SEBI (DP) RegulationCompany Updatelow impact
- Unjha Formulations Limited files annual financial statements for the fiscal year ended 31 March 2026Company Updatelow impact
Cruxal's analysis: Unjha Formulations Limited has submitted its annual financial statements, including the…
Read the full analysis - Unjha Formulations Limited Announces Voting Results of 32nd Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Unjha Formulations Limited has disclosed the voting results for its 32nd Annual General…
Read the full analysis - Unjha Formulations Ltd files distribution schedule as per SEBI LODR regulationsCompany Updatelow impact
Cruxal's analysis: Unjha Formulations Ltd has submitted its distribution schedule in compliance with SEBI…
Read the full analysis - Unjha Formulations Ltd releases Cash Flow Statement for FY2026Company Updatelow impact
Cruxal's analysis: Unjha Formulations Ltd has filed its Cash Flow Statement for the financial year ended…
Read the full analysis - Unjha Formulations Ltd releases Cash Flow Statement for FY 2025-26Company Updatelow impact
Cruxal's analysis: Unjha Formulations Ltd has filed its Cash Flow Statement for the financial year ended…
Read the full analysis - Unjha Formulations Limited Concludes 32nd Annual General Meeting; Reappoints Managing DirectorAGM/EGMlow impact
Cruxal's analysis: Unjha Formulations Limited has successfully concluded its 32nd Annual General Meeting…
Read the full analysis - Unjha Formulations Limited reports Q1 FY2027 financial results with significant YoY decline in revenue and net profitCompany Updatehigh impact
Cruxal's analysis: Unjha Formulations Limited reported a decline in performance for the quarter ended 30…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.